Investigate the protective effect of chronic MitoQ supplementation on cardiovascular toxicity induced by doxorubicin-based adjuvant chemotherapy in breast cancer patients.
Test the hypothesis that chronic MitoQ supplementation in breast cancer patients treated with doxorubicin prevents: 1. increased mitochondrial oxidative stress; 2. the increase in cardiac markers (B-type natriuretic peptide and troponin I); 3. changes in left ventricular deformity (speckle tracking, strain) and reduction in LVEF; 4. endothelium-dependent dysfunction of peripheral vascular beds; 5. the increase in endothelial microvesicles; 6. the increase in material stiffness; 7. the elevation of central blood pressure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
44
Mitoquinone pill, 20 mg/day
Placebo pill, 20 mg/day
Changes of the left ventricular deformity and reduction in left ventricular ejection fraction
Cardiac function changes (Strain and Simpson's monoplanar)
Time frame: 3 Months
Systemic markers of oxidative stress
Mitochondrial oxidative stress; Cardiac markers (B-type natriuretic peptide and troponin I);
Time frame: 3 Months
Endothelium-dependent dysfunction of peripheral vascular beds
changes in the endothelium-dependent function of peripheral vascular beds
Time frame: 3 Months
Arterial stiffness
Increase in the arterial stiffness
Time frame: 3 Months
Central blood pressure
Alterations on the central blood pressure
Time frame: 3 Months
Physical capacity
Reduction in the peak oxygen uptake
Time frame: 3 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.